The classic scenario is in mature B-cell lymphomas, such as Burkitt lymphoma, in which the IGH enhancer activates MYC, or follicular lymphoma, in which the IGH enhancer activates BCL2. This evidence concerns the gene BCL2 and Burkitt lymphoma.